Protocol Title

AG0403BT

Conference Presentation Reference

1. Australasian Gastrointestinal Trials Group; Shannon JA, Goldstein D, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Jones-Murphy M. A phase II trial of gemcitabine in fixed dose rate infusion combined with low dose cisplatin in patients with inoperable biliary tract carcinomas. Gastrointestinal Cancers Symposium; 25–27 Jan 2008; Orlando. Abstract 243.
2. Goldstein D, Shannon J, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Adams K; for the Australasian Gastro-Intestinal Trials Group. ABC: an AGITG trial of fixed dose rate gemcitabine and cisplatin for patients with advanced biliary tract cancer. 43rd Annual Scientific Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago. Journal of Clinical Oncology 2007; 25 (18S, Part 1): 15015.

Aim

Biliary tract cancers are uncommon; as a result it is not a well-studied disease and treatment options for this condition are limited. This study will assess the impact of a new combination of chemotherapy drugs on the growth of the cancer and the undesirable side-effects of treatment.

Principal Investigator

Conjoint Professor David Goldstein, Medical Oncologist Prince of Wales Hospital NSW.
Doctor Jenny Shannon, Medical Oncologist Nepean Hospital NSW.

Funding

Eli Lilly Australia P/L